SBC Medical Q4 2025 net income up 117% to $14M; EPS $0.14, revenue $40M (-11% YoY)

SBC Medical Group Holdings Inc

Net income attributable to SBC Medical Group was $14M, up 117% YoY; EPS $0.14, up 133% YoY.
Total revenues $40M, down 11% YoY; EBITDA $14M, down 35% YoY; EBITDA margin 34% vs 46% prior year.
Franchise locations increased 34 to 283; customer count in LTM 6.6M, up 12% YoY; repeat rate 72%.
Return on equity improved to 23%, up 9.8 percentage points YoY.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SBC Medical Group Holdings Inc reported fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve mont results: revenue Total revenues were $40 million, net income Net Income attributable to SBC Medical Group was $14 million, EPS earnings per share ... was $0.14.

Period: fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve mont
Revenue: Total revenues were $40 million
Net income: Net Income attributable to SBC Medical Group was $14 million
EPS: earnings per share ... was $0.14
Result: reported results

Exact text from the filing

year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025) Fourth Quarter 2025 Highlights ● Total revenues were $40 million, representing an 11% year-over-year decrease. ● Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. ● Earnings per share

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

SBC Medical Group Holdings Inc filing history →

Source: SEC EDGAR

accession 0001493152-26-013078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.